Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview

Voyager Therapeutics

31/07/2026 12:25

Voyager Therapeutics Inc VYGR.OQ VYGR.O is expected to  show a fall in quarterly revenue when it reports  results on August 4 (estimated) for the period ending June 30 2026
The Lexington Massachusetts-based  company is expected to report a 9.1% decrease in revenue to $4.728 million from $5.2 million a year ago, according to the mean estimate from 9 analysts, based on LSEG data.
​LSEG's mean analyst estimate for Voyager Therapeutics Inc is for a loss of 48 cents per share. 
The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 11 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Voyager Therapeutics Inc is $12.00, about 283.4% above its last closing price of $3.13
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.56
-0.55
-0.47
Beat
14.7
Dec. 31 2026
-0.51
-0.51
-0.46
Beat
9.9
Sep. 30 2025
-0.53
-0.52
-0.47
Beat
9.7​
Jun. 30 2025
-0.54
-0.53
-0.57
Missed
-8.5
​​Mar. 31 2025
-0.46
-0.45
-0.53
Missed
-18
Dec. 31 2024
-0.34
-0.37
-0.59
Missed
-61​
Sep. 30 2024
-0.40
-0.45
-0.16
Beat
64.7
Jun. 30 2024
-0.41
-0.41
-0.18
Beat
56
This summary was machine generated July 31 at 11:25 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)